What to do: If you have an allergy to milk, do not consume the recalled product
Audience: General public
Recall class: Class 1
Affected products
Brand
Product
Size
UPC
Codes
Searay
Sauerkraut Fish (Szechuan Style) Spicy
400 g
8 27510 00494 2
Best Before: 2022 JN 15 Lot number: 2012201CHG
Issue
Searay Foods Inc. is recalling Searay brand Sauerkraut Fish (Szechuan Style) Spicy from the marketplace because it may contain milk which is not declared on the label.
The recalled product has been sold in Alberta, British Columbia, Manitoba, Nova Scotia, Ontario, Quebec, and Saskatchewan and may have been distributed in other provinces and territories.
What you should do
Check to see if you have the recalled product in your home
If you have an allergy to milk, do not consume the recalled product as it may cause a serious or life-threatening reaction
Recalled products should be thrown out or returned to the location where they were purchased
This recall was triggered by Canadian Food Inspection Agency (CFIA) test results.
There have been no reported reactions associated with the consumption of this product.
What is being done
The CFIA is conducting a food safety investigation, which may lead to the recall of other products. If other high-risk products are recalled, the CFIA will notify the public through updated food recall warnings.
The CFIA is verifying that industry is removing the recalled product from the marketplace.
The IAMStm brand, proudly part of the Mars family of brands, announced today the launch of the IAMStm Puppy Hub and Kitten Hub, two online tools featuring expert knowledge and advice for new and soon-to-be pet parents. Each Hub will bring...
Today, TELUS Health announced a collaboration with Nova Scotia Health (NSH) to enable residents of Nova Scotia to access their primary care information through the YourHealthNS app. This health data interoperability initiative marks the first...
The global Digital Healthcare Market, valued at $220.10 billion in 2024, is on a trajectory of rapid expansion, with projections indicating it will soar to $836.10 billion by 2031, growing at a compound annual growth rate (CAGR) of 21% from 2024 to...
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period.
The...
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...